Want to see SE:ACOU full AI Analyst Report?

AcouSort AB (ACOU) Price & Analysis

0 Followers

ACOU Stock Chart & Stats

kr3.72

-kr0.07(-1.88%)

At close: Jul 27 4:00 PM EDT

kr3.72

-kr0.07(-1.88%)

Day’s Range― - ―

52-Week Rangekr2.03 - kr5.16

Previous CloseN/A

Volume11.66K

Average Volume (3M)29.24K

Market Cap

kr73.02M

Enterprise Valuekr75.16M

Total Cash (Recent Filing)kr14.57M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding21,163,902

10 Day Avg. Volume27,764

30 Day Avg. Volume29,240

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)3.27

Price to Sales (P/S)7.79

P/FCF Ratio-3.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr10.40M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces solvency risk and provides durable financial flexibility. Over a multi-month horizon this allows management to prioritize product development, strategic partnerships or selective commercialization without immediate refinancing pressure, supporting long-term optionality.

Improving Revenue MomentumAccelerating top-line growth signals improving market adoption of the product suite. Sustained revenue momentum helps absorb fixed costs and lays a clearer path to scale economics; if maintained over quarters it materially improves prospects for stabilizing margins and achieving operational leverage.

Differentiated Technology & Target MarketsA unique, label-free acoustic separation platform targets high-growth, structurally supportive markets (diagnostics, cell therapy). This technological differentiation can create durable competitive advantage and channel opportunities with instrument integrators and therapy developers if clinical and workflow validation continues.

Bears Say

Negative Gross Profit & Persistent LossesNegative gross profit indicates unit economics are currently unfavourable; without meaningful cost reduction, pricing power, or scale benefits the business cannot generate sustainable margins. Persistent operating and net losses over time threaten long-term viability absent structural improvements.

Weak Cash Generation / Declining FCFInconsistent and negative cash generation, combined with a steep free-cash-flow decline, creates an ongoing funding requirement. Over months this raises the likelihood of dilutive financing or constrained investment in commercialization and R&D, limiting the company's ability to execute growth initiatives independently.

Eroding Equity & Very Low ReturnsDeeply negative ROE and declining equity reflect capital erosion from ongoing losses. This reduces the shareholder capital buffer and can increase difficulty and cost of raising future capital, weakening the firm's resilience to setbacks and limiting strategic flexibility in the medium term.

ACOU FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was kr2.03 and its highest was kr5.16 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is kr73.02M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is Aug 26, 2026 which is in 13 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on May 27, 2026. The company reported -kr0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.112.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -kr0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.139%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in SE:ACOU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.